Research Analysts Issue Forecasts for FENC Q3 Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 earnings estimate for Adherex Technologies to ($0.09) per share, down from the previous estimate of ($0.04).
• Despite the pessimistic outlook, HC Wainwright maintains a "Buy" rating with a target price of $13.00, while other analysts have varied ratings ranging from "Strong Buy" to "Hold."
• Adherex Technologies missed its recent earnings estimate, reporting ($0.11) EPS for the quarter, compared to the consensus estimate of ($0.06).

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for Adherex Technologies in a note issued to investors on Thursday, August 21st. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.09) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright currently has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Adherex Technologies' current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies' FY2025 earnings at ($0.25) EPS and FY2026 earnings at $0.65 EPS.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $9.76 million during the quarter, compared to the consensus estimate of $9.52 million.

Several other research firms have also recently weighed in on FENC. Wall Street Zen upgraded shares of Adherex Technologies from a "hold" rating to a "buy" rating in a research report on Sunday, August 17th. Craig Hallum boosted their price target on shares of Adherex Technologies from $13.00 to $14.00 and gave the company a "buy" rating in a report on Friday, August 15th. Finally, Zacks Research cut shares of Adherex Technologies from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Adherex Technologies currently has a consensus rating of "Buy" and an average price target of $13.33.

Adherex Technologies Price Performance

Shares of NASDAQ FENC traded up $0.03 during trading on Monday, hitting $8.68. The company had a trading volume of 49,964 shares, compared to its average volume of 66,512. Adherex Technologies has a 52 week low of $3.96 and a 52 week high of $9.42. The business's 50-day moving average is $8.45 and its 200 day moving average is $7.23.

Institutional Investors Weigh In On Adherex Technologies

Several institutional investors and hedge funds have recently modified their holdings of FENC. AQR Capital Management LLC acquired a new stake in shares of Adherex Technologies in the 1st quarter valued at $66,000. Wells Fargo & Company MN lifted its position in Adherex Technologies by 31.6% during the 4th quarter. Wells Fargo & Company MN now owns 13,152 shares of the company's stock worth $83,000 after acquiring an additional 3,155 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Adherex Technologies during the first quarter valued at about $90,000. Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Adherex Technologies during the fourth quarter valued at about $97,000. Finally, MetLife Investment Management LLC acquired a new position in shares of Adherex Technologies during the fourth quarter valued at about $99,000. Institutional investors and hedge funds own 55.51% of the company's stock.

Insider Activity

In related news, Director Rosty Raykov sold 10,000 shares of Adherex Technologies stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $8.09, for a total value of $80,900.00. Following the completion of the sale, the director owned 55,878 shares of the company's stock, valued at approximately $452,053.02. The trade was a 15.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 31,119 shares of company stock valued at $254,546. 10.98% of the stock is currently owned by insiders.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.